Vitrolife interim report January - March 2003

· Net sales for core activities increased by 18 % to a total of SEK 25.9 million (22.0).
· Gross margin increased and amounted to 62 % (50 %).
· The group's net loss totalled SEK -0.6 million (-3.7).
· Vitrolife receive USA patent for a new technique for cryo-preservation of living cells, named Vitroloop.

Gothenburg, March 23, 2003.

Vitrolife AB (Publ)

For further information, please contact:
Vitrolife
Acting CEO: Magnus Nilsson
Tel: +46 31 721 80 00
Mobile +46 708 22 80 61
[email protected]

CFO and IR agent:
Margareta Fischer
Tel: +46 31 721 80 00
Mobile: +46 708 22 80 13
[email protected]

Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and four wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado), A-Life Ltd. (Edinburgh, Scotland), and A-Life Inc. (Newport Beach, California). The group's operations focused on three geographic areas.

· Europe/Middle East
· North America
· Rest of the World

Vitrolife's business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs.